TrialAnnals of neurology2025

Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis.

Bruce A C Cree et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.